In the second kidney disease study, Aprovel reduced the relative risk of a doubling of blood creatinine levels, needing a kidney transplant or dialysis, or death during the study by 20% in comparison with placebo.
nausea (feeling sick) or vomiting, fatigue (tiredness) and increases in blood creatine kinase levels (an enzyme found in muscles).
Aprovel should not be used in people who may be hypersensitive (allergic) to irbesartan or any of the other ingredients.
Other information about Aprovel: The European Commissio n granted a marketing authorisation valid throughout the European Union
